Venetoclax (Venclexta) - chronic lymphocytic leukemia View of Venetoclax (Venclexta) | Canadian Journal of Health Technologies Return to Article DetailsVenetoclax (Venclexta)
Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma 25 FEBRUARY 2025 Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma Pirtobrutinib with venetoclax and rituximab is currently in clinical development for the treatment of chronic lymphocytic
Venetoclax with azacitidine for treating acute myeloid leukaemia following allogeneic stem cell transplantation Venetoclax with azacitidine for treating acute myeloid leukaemia following allogeneic stem cell transplantation - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * News * Resources Get in touch * * A world leading Horizon Scanning Facility The NIHR MedicinesMarch 2024 * Who we are * Meet the Team * Our Mission * Our Values * What we do * Emerging horizon * Transitional horizon * Imminent horizon * Our Networks * Our Stakeholders * Our Work with NICE * Health & Life Sciences Ecosystem * Engage * Industry * Public Involvement * Capacity Building * Events * News * Resources * Contact 29 May 2024 Venetoclax with azacitidine for treating acute myeloid
Venetoclax Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs and health
Venetoclax (venclexta) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs
Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39 1 Translation of addendum A20-76 Venetoclax (chronische lymphatische Leukämie) – Addendum zum Auftrag A20-39 (Version 1.0; Status: 25 September 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 September 2020 1.0 Commission: A20-76 Version: Status: IQWiG Reports – Commission No. A20-76 Venetoclax (chronic lymphocytic leukaemia) – Addendum to Commission A20-391 Addendum A20-76 Version 1.0 Venetoclax – Addendum to Commission A20-39 25 September 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i
Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V 1 Translation of addendum A21-138 Venetoclax (akute myeloische Leukämie) – Addendum zum Auftrag A21-82 (Version 1.0; Status: 12 November 2021). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 12 November 2021 1.0 Commission: A21-138 Version: Status: IQWiG Reports – Commission No. A21-138 Venetoclax (acute myeloid leukaemia) – Addendum to Commission A21-821 Addendum A21-138 Version 1.0 Venetoclax – Addendum to Commission A21-82 12 November 2021
Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Venetoclax (akute myeloische Leukämie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 September 2021). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-82 Venetoclax (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-82 Version 1.0 Venetoclax (acute myeloid leukaemia) 13 September 2021 Institute for Quality and Efficiency
Ibrutinib (Imbruvica) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) Rothschedl, E. and Wolf, S.(2022):Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Oncology Fact
Venetoclax (Venclyxto) - acute myeloid leukaemia Published 07 November 2022 Statement of advice SMC2509 venetoclax 10mg, 50mg and 100mg film-coated tablets (Venclyxto®) AbbVie Ltd 07 October 2022 ADVICE: in the absence of a submission from the holder of the marketing authorisation venetoclax (Venclyxto®) is not recommended for use within NHSScotland. Indication under review
Venetoclax (Venclyxto) - acute myeloid leukaemia (AML) 1 Published 11 April 2022 1 SMC2412 venetoclax 10mg, 50mg and 100mg film-coated tablets (Venclyxto®) AbbVie 04 March 2022 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life and orphan equivalent medicine process venetoclax (Venclyxto ®) is accepted for use within NHSScotland. Indication under review: in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. In a phase III study
Venetoclax (Venclyxto) - chronic lymphocytic leukaemia (CLL) 1 1 Published 09 May 2022 SMC2427 venetoclax 10mg, 50mg, 100mg film-coated tablets (Venclyxto®) AbbVie Ltd 8 April 2022 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission venetoclax (Venclyxto®) is accepted for restricted use within NHSScotland. Indication under review: In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) SMC restriction: in patients without del (17p)/TP53 mutation who are fit
Venetoclax (Venclyxto) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML) Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML). Update August 2021 - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML). Update August 2021 Wolf, S.(2021):Venetoclax (Venclyxto®) in combination with a hypomethylating agent
Venetoclax (Venclyxto): updated recommendations on tumour lysis syndrome (TLS) Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS) - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use * Universal Credit account: sign in 1. Home 2. Drug Safety Update Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS) Fatal cases of tumour lysis syndrome (TLS) have been reported, some occurring in patients with chronic lymphocytic leukaemia receiving the lowest venetoclax dose used in the dose-titration schedule. For all patients, it is important to strictly adhere